Results 141 to 150 of about 18,439,231 (382)

Why Does Employee Choose Participatory Performance Measurement? [PDF]

open access: yes, 2015
Tujuan dari penelitian ini adalah untuk menyelidiki mengapa karyawan memilih pengukuran kinerja secara partisipatoris. Munandar (2015) mengemukakan bahwa karyawan lebih menyukai pengukuran kinerja secara partisipatoris dalam melakukan penilaian evaluasi ...
Munandar, A. (Agus)
core  

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

open access: yesMolecular Oncology, EarlyView.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink   +6 more
wiley   +1 more source

Pursuing Equity in Performance Measurement. [PDF]

open access: yesCirculation, 2023
Heidenreich P, Sandhu A.
europepmc   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

open access: yesMolecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker   +14 more
wiley   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

open access: yesMolecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen   +13 more
wiley   +1 more source

FEATURES CONCERNING COMPETITIVE PERFORMANCE MEASUREMENT [PDF]

open access: yes
Innovation and competitiveness are the main vectors of social-economic progress of every country. Starting from this general context and considering the particular context wherein Romania is, which strongly impose the growth of economic competitiveness ...
Cristina Coculescu
core  

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

open access: yesMolecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi   +6 more
wiley   +1 more source

Performance measurement in blind audio source separation

open access: yesIEEE Transactions on Audio, Speech, and Language Processing, 2006
E. Vincent, R. Gribonval, C. Févotte
semanticscholar   +1 more source

Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients

open access: yesMolecular Oncology, EarlyView.
We quantified and cultured circulating tumor cells (CTCs) of 62 patients with various cancer types and generated CTC‐derived tumoroid models from two salivary gland cancer patients. Cellular liquid biopsy‐derived information enabled molecular genetic assessment of systemic disease heterogeneity and functional testing for therapy selection in both ...
Nataša Stojanović Gužvić   +31 more
wiley   +1 more source

Home - About - Disclaimer - Privacy